Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer

PHASE4CompletedINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Colo-rectal Cancer

Interventions

DRUG

Bevacizumab

bevacizumab (7.5mg/kg every 21 days) for minimum of 3 cycles

Trial Locations (1)

Baghdad Medical city, Baghdad

All Listed Sponsors

lead

Mohammed Mahmood Mohammed

OTHER